BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32492752)

  • 41. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
    He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
    Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Giant cell tumors and pseudogiant cell tumors of the jaws].
    Barthélémy I; Mondié JM
    Rev Stomatol Chir Maxillofac; 2009 Sep; 110(4):209-13. PubMed ID: 19682716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
    Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
    EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Giant Cell-Rich Tumors of Bone.
    Hartmann W; Harder D; Baumhoer D
    Surg Pathol Clin; 2021 Dec; 14(4):695-706. PubMed ID: 34742488
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.
    Dalin MG; Zou Z; Scharin-Täng M; Safari R; Karlsson C; Bergo MO
    Cardiovasc Res; 2014 Feb; 101(2):229-35. PubMed ID: 24259500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
    Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
    Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
    Mazurenko NN; Gagarin IM; Tsyganova IV; Mochal'nikova VV; Breder VV
    Vopr Onkol; 2013; 59(6):751-5. PubMed ID: 24624786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brown Tumors of the Jaws: A Retrospective Study.
    Fedhila M; Belkacem Chebil R; Marmouch H; Terchalla S; Ayachi S; Oueslati Y; Oualha L; Douki N; Khochtali H
    Clin Med Insights Endocrinol Diabetes; 2023; 16():11795514231210143. PubMed ID: 37942058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary hyperparathyroidism presenting as a giant cell tumor of the jaws.
    Pawlak W; Bohdanowicz-Pawlak A; Bolanowski M; Szymczak J; Bednarek-Tupikowska G; Luczak K
    Neuro Endocrinol Lett; 2013; 34(2):107-10. PubMed ID: 23645306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.